Latest Content

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

Expanded astigmatism parameters are expected for PRECISION1, PRECISION7, and TOTAL30 contact lenses.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

Mile Brujic, OD, FAAO, details his presentation on how eye care providers can best equip themselves with identifying and mitigating toxicities caused by antibody drug conjugates.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The company said the expanded portfolio will be available in the US and Canada this summer.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

A newly developed diagnostic system, CaptureTumor (CaT), driven by AI and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation for detecting rare ocular surface malignancies.

In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

A case study that highlights the importance of multimodal imaging in practice for early identification of rare inherited retinal dystrophies.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The lens is scheduled to become available in the US in fall 2026.